Fig. 5: Pathological complete response by PD-L1 status. | npj Breast Cancer

Fig. 5: Pathological complete response by PD-L1 status.

From: A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (TNBC) - NCI 10013

Fig. 5: Pathological complete response by PD-L1 status.The alt text for this image may have been generated using AI.

a PD-L1 status assessed by VENTANA PD-L1 (SP142) assay in patients treated with chemotherapy alone and chemotherapy plus atezolizumab. Orange areas represent Arm A chemotherapy only. Blue areas represent Arm B chemotherapy plus atezolizumab. b PD-L1 status assessed by multiplex immunofluorescence in patients treated with chemotherapy alone and chemotherapy plus atezolizumab. PD-L1-positive status represents the percent positive cells on inflammatory cells (PD-L1-positive cytokeratin-negative or CD8-positive cells), divided by the total number of cytokeratin-negative and CD8 positive cells. Orange areas represent Arm A chemotherapy only. Blue areas represent Arm B chemotherapy plus atezolizumab. Error bars represent standard error of pCR rate.

Back to article page